ARFXF News and Press, Amorfix Life Sciences Ltd From 11/14/19

ProMIS Neurosciences Announces Third Quarter 2019 Results Canada NewsWire TORONTO and CAMBRIDGE, MA, Nov. 14, 2019 Company continues to expand its portfolio of highly selective antibodies targeting root cause of Alzheimer's, ALS and Parkinson's disease TORONTO and CA...

ProMIS Neurosciences Undertaking $6.5M Private Placement Canada NewsWire TORONTO, Nov. 13, 2019 /NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ./ TORONTO , Nov. 13, 2019 /CNW/ - ProMIS Neurosciences, Inc. (" ProMIS " or the " Co...

ProMIS Neurosciences outlines best-in-class approach to amyloid-beta-targeting drug candidates for Alzheimer's disease Canada NewsWire TORONTO and CAMBRIDGE, MA, Nov. 7, 2019 Dr. Johanne Kaplan highlights need for precision selectivity for the toxic form of amyloid beta...

New resources detail positive impact of aducanumab pivotal trial results and recent progress of ProMIS pipeline programs TORONTO and CAMBRIDGE, MA , Oct. 24, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the disco...

ProMIS Neurosciences advances ALS program selectively targeting toxic form of TDP-43 Canada NewsWire TORONTO and CAMBRIDGE, MA, Oct. 23, 2019 Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases ...

ProMIS Neurosciences advances Alzheimer's disease program targeting neurotoxic forms of tau Canada NewsWire TORONTO and CAMBRIDGE, MA, Oct. 17, 2019 Data show antibody candidates bind toxic forms of tau and inhibit its propagation in a cellular model TORONTO and CA...

ProMIS Neurosciences Identifies Novel Antibody Candidates for Multiple System Atrophy Canada NewsWire TORONTO and CAMBRIDGE, MA, Oct. 8, 2019 Antibodies show highly selective binding to pathogenic forms of alpha-synuclein implicated in multiple system atrophy TORONTO a...

The following slide deck was published by ProMIS Neurosciences, Inc. in conjunction with this Read more ...

TORONTO and CAMBRIDGE, MA , Sept. 16, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurode...

Company to showcase its innovative Alzheimer's, Parkinson's and ALS programs TORONTO and CAMBRIDGE, MA , Sept. 3, 2019 /PRNewswire/ - ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics ...